Premium
Immunodiagnosis of prostate cancer: An evaluation of cell‐mediated immunity
Author(s) -
Bhatti Rashid A.,
Guinan Patrick D.,
Nagubadi Subba R.,
Khin Winston
Publication year - 1982
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.2990030411
Subject(s) - antigen , prostate , medicine , immunity , adenocarcinoma , cell mediated immunity , prostate specific antigen , prostate cancer , stage (stratigraphy) , oncology , in vitro , cancer , cellular immunity , disease , immunology , immune system , cancer research , biology , paleontology , biochemistry
Leukocyte adherence inhibition (LAI), a suggested in vitro correlate of cell‐mediated immunity, was employed to identify patients with various stages of adenocarcinoma of the prostate on the basis of their degree of reactivity to prostatic tumor‐associated antigens. Eighty‐one percent of the patients and 56% of the controls were identified correctly. The efficiency of LAI was based on the sensitivity and specificity of the test. Our data revealed the absence of any correlation between patients' clinical stage of the disease and their in vitro reactivity to prostatic tumor‐associated antigens.